DeutschNewstral
Article
bizjournals.com on 2017-07-13 15:41
Durham company bulks up executive suite as cancer therapy development moves forward
Related news
- Gene therapy firm expanding in RTP bulks up C-suite with industry veteranbizjournals.com
- Durham clinical company bolsters C-suite for 'growth spurt'bizjournals.com
- WDurham company bets $100M on possible COVID therapywraltechwire.com
- Executive Voice: Opendoor leader talks strategy in Raleigh, Durham marketsbizjournals.com
- Executive Voice: Providing the spark for innovation in Durhambizjournals.com
- Executive Voice: He’s an advocate for Black business in Durhambizjournals.com
- Executive Voice: Support calls surge for growing firm in Durhambizjournals.com
- Executive Voice: Andrea Reusing — Lantern and The Durhambizjournals.com
- Executive Voice: Her Durham firm pioneers transformation of medicinebizjournals.com
- Executive Voice: His passion for building begins in Durhambizjournals.com
- Durham drugmaker pushes forward with its latest clinical cancer treatmentbizjournals.com
- Durham stays hot to start 2021: Gene therapy firm plans 200-job, $80M operationbizjournals.com
- California gene therapy firm plans 200-job, $80M operation in Durhambizjournals.com
- $842M gene therapy deal to boost development by Roivant spinoff in Durhambizjournals.com
- Durham biotech uses new funding to acquire gene therapy for eye diseasebizjournals.com
- Gene therapy firm Bluebird Bio, with Durham site, to split into two companiesbizjournals.com
- Texas gene therapy company picks Durham for 200-job, $75 million operationbizjournals.com
- Gene therapy firm considered Wake County before picking Durham for 200-job facilitybizjournals.com
- Executive Voice: McKinsey veteran's big bet in Durham with digital insurance firmbizjournals.com